References
- Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34
- Littlewood TJ. Management options for cancer therapy-related anaemia. Drug Safety 2002;25:525–35
- Guest JF, Munro V, Cookson RF. The annual cost of blood transfusions in the United Kingdom. Clin Lab Haematol 1998;20:111–8
- NHS Executive. Government accepts advice on leucodepletion from spongiform encephalopathy advisory committee. London: Department of Health. Press release 1998/295
- Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med 2003;13:205–18
- Currie CJ, Patel TC, McEwan P, et al. Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service. Transfus Med 2003;14:19–24
- UNISON pay and conditions. Available from http://www.unison.org.uk/pay/payscales.asp [Last accessed June 9th, 2006]
- Crémieux PY, Barrett B, Anderson K, et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000;18: 2755–61
- De Cock E, van Bellinghen L, Fabre-Guillevin P, et al. Assessing provider time and costs for red blood cell (RBC) transfusions in anaemia management of cancer patients using the activity-based costing (ABC) method in France. Value Health 2003; 6:735
- Barrett-Lee PJ, Bailey NP, O’Brien MER, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93–7
- McClelland B, Contreras M. Appropriateness and safety of blood transfusion. BMJ 2005;330:104–5
- NBS National Prices Document. Available from http://www.blood.co.uk/hospitals/library/pdf/components/national_prices_05_06.pdf [Last accessed 13th August 2006]
- Littlewood TJ. Management options for cancer therapy-related anaemia. Drug Safety 2002;25:525–35
- Cheer SM, Wagstaff AJ. Epoetin beta – a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004;64:323–46
- Johansson JE, Wersall P, Brandberg Y, et al. efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. Scand J Urol Nephrol 2001;35:288–94
- Cavill I. Reducing blood transfusion. Focus should be on improving patients’ ability to make own blood. BMJ 2002;325:655
- Joint response – National Blood Service and Welsh Blood Service. Health technology appraisal. Cancer treatment induced anaemia: epoetin (alpha and beta) and darbepoetin alpha. Available from http://www.nice.org.uk/page.aspx?o=263335 [Last accessed June 9th, 2006]
- NHS Executive. Better blood transfusion. Appropriate use of blood. London: Department of Health. Health Service Circular 2002
- Bosanquet N, Tolley K. Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 2003;19: 643–50